Argus
•
Apr 08, 2026
EXEL: Raising target price to $48.00
Summary
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercial
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Alnylam Pharmaceuticals, Inc.
May 01, 2026
•
ALNY
Analyst Report: Amgen Inc.
May 01, 2026
•
AMGN
Analyst Report: Merck & Co., Inc.
May 01, 2026
•
MRK
Analyst Report: Ionis Pharmaceuticals, Inc.
Apr 30, 2026
•
IONS
Analyst Report: Bristol-Myers Squibb Company
Apr 30, 2026
•
BMY
